- Investors must track Medicare coverage decisions and Abbott's sales trajectory, as these determine royalty streams and ...
Colon cancer does not always begin with obvious pain or visible bleeding. Sometimes the first clue is a persistent change in ...
Morning Overview on MSN
Atezolizumab plus chemo won FDA approval for some stage III colon cancers
On Oct. 8, 2026, the Food and Drug Administration approved atezolizumab, sold as Tecentriq by Genentech, together with chemotherapy for adults and children as young as two with Stage III colon cancer ...
The FDA has approved atezolizumab with chemotherapy after surgery for stage III colon cancer with deficient mismatch repair, ...
Mayo Clinic says tt three years, 86.3% of patients who received immunotherapy plus chemotherapy were alive and free of ...
The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...
The FDA has approved atezolizumab with chemotherapy for adjuvant treatment of stage III dMMR colon cancer after the phase III ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) and Tecentriq Hybreza ® ...
Burgess has survived colon cancer three times. She represents one of many instances of cancer rates surging in younger people.
She’s now been diagnosed with colorectal cancer in her teens, 20s and 30s. A little-known syndrome may be one reason why more young people are at higher risk for the disease.
I was hospitalized for the first time in my life for colon cancer surgery—it was okay to say, 'I'm scared'In my previous ...
Researchers at the Massachusetts Institute of Technology (MIT) have identified a biological pathway through which a high-fat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results